Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
Kyowa Kirin on February 9 unveiled a new medium- to long-term strategy, Vision 2030 and Beyond, setting out goals to acquire more than 20 new pipeline assets and score US FDA approval for over 10 indications by the early 2030s.…
To read the full story
BUSINESS
- Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
March 23, 2026
- Chugai Files Device Component of Ranibizumab Eye Implant in Japan
March 23, 2026
- Shionogi’s Zurzuvae, Kissei’s Yselty Now Available in Japan
March 23, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…